Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Icatibant

Nature Reviews Drug Discovery volume 7, pages 801–802 (2008)Cite this article

Abstract

Credit: Icatibant

In July 2008, icatibant (Firazyr; Jerini), a bradykinin B2 receptor antagonist, was granted market authorization by the European Commission for the symptomatic treatment of acute attacks of hereditary angioedema.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Icatibant.

References

  1. Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).

    Article  Google Scholar 

  2. Gompels, M. M. et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139, 379–394 (2005).

    Article  CAS  Google Scholar 

  3. Nussberger, J. et al. Plasma bradykinin in angio-oedema. Lancet 351, 1693–1697 (1998).

    Article  CAS  Google Scholar 

  4. Marceau. F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. Nature Rev. Drug Discov. 3. 845–852 (2004).

    Article  CAS  Google Scholar 

  5. Hock, F. J. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102, 769–773 (1991).

    Article  CAS  Google Scholar 

  6. Wirth, K. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102, 774–777 (1991).

    Article  CAS  Google Scholar 

  7. European Medicines Agency (EMEA). European Public Assessment Report – Firazyr. EMEA web site [online], (2008).

  8. Bork, K. et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 19, 1497–1503 (2007).

    Article  Google Scholar 

  9. Bork, K. et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am. J. Med. 120, 987–992 (2007).

    Article  Google Scholar 

  10. Bork, K. et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45, 1774–1784 (2005).

    Article  CAS  Google Scholar 

  11. Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416–422 (2007).

    Article  CAS  Google Scholar 

  12. Choi, G. et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47, 1028–1032 (2007).

    Article  CAS  Google Scholar 

  13. IMS Health Analysis, IMS MIDAS Quantum (2008).

  14. Hilliker, I. et al. Jerini (Credit Suisse Securities Europe, 27 Feb 2008).

  15. White, B. Jerini (Deutsche Bank Biotechnology, 1 May 2008).

Download references

Author information

Authors and Affiliations

  1. Konrad Bork is at the Department of Dermatology, Johannes Gutenberg University, Universitaets-Hautklinik, Langenbeckstrasse 1, 55131 Mainz, Germany. bork@hautklinik.klinik.uni-mainz.de,

    Konrad Bork

  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Konrad Bork
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

K.B. was closely involved in the conduct of clinical trials with icatibant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bork, K., Yasothan, U. & Kirkpatrick, P. Icatibant. Nat Rev Drug Discov 7, 801–802 (2008). https://doi.org/10.1038/nrd2694

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2694

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing